Helixgate

Helixgate

Uncategorized

African Trypanosomes Use a Molecular Shredder to Avoid Detection in the Bloodstream

Published

on

In mammalian hosts, the African trypanosome parasite replicates freely in the bloodstream, despite being fully exposed to the immune system. To do this, the pathogen relies on the stochastic switching of a Variant Surface Glycoprotein (VSG) for immune evasion.

Now, a study presents the newly discovered ESB2 protein—an active RNA endonuclease—which acts as a “molecular shredder,” allowing the parasite to avoid detection by fine-tuning expression of virulence genes through specialized RNA decay.

Transmitted by the bite of the tsetse fly, if left untreated, the parasites invade the central nervous system, causing neurological issues including severe sleep disruptions, confusion, and coma. This understanding of a previously undescribed mechanism of how the parasite avoids detection with incredible precision may allow researchers to identify new vulnerabilities in its life cycle. It may open the door for future treatments for sleeping sickness—a disease that continues to have a devastating impact on communities across sub-Saharan Africa.

This work is published in Nature Microbiology in the paper, “Specialized RNA decay fine-tunes monogenic antigen expression in Trypanosoma brucei.

“We’ve discovered that the parasite’s secret to staying invisible isn’t just what it prints, but what it chooses to redact,” noted Joana Faria, PhD, leader of the research group at the University of York. “By placing a ‘molecular shredder’ directly inside its ‘protein factory,’ the parasite can edit its genetic manual in real-time. This suggests a fundamental shift in how we view infection: survival for many organisms may depend less on how they issue genetic instructions and more on how they destroy them at the source.”

The discovery provides an answer to a lingering question in the parasite’s biology that has challenged scientists for 40 years. The genetic manual for the VSG also contains several genes needed for survival and immune evasion. Logic suggests that when the parasite follows these genetic instructions, it should produce equal amounts of each protein. However, the parasite somehow produces a mountain of cloak proteins but only a tiny amount of helper proteins.

By identifying the ESB2 protein, the York team discovered that the parasite controls its genetic messages through destruction rather than just production. ESB2 sits directly inside the parasite’s protein factory, known as the Expression Site Body (ESB). ESB2 acts as a “molecular blade,” ensuring the parasite expresses exactly what it needs to remain hidden from the host’s immune system.

The researchers applied TurboID-mediated proximity labelling mass spectrometry (PL-MS) to “map the ESB post-transcriptional network, identifying three new components: ESB-

associated protein 1 (ESAP1) and ESB-specific proteins 2 and 3 (ESB2 and 3).” They then characterized ESB2 as an RNA endonuclease that negatively regulates ESAG transcripts.

Crucially, they write, they demonstrate that “ESB2 recruitment depends on both its own catalytic activity and a hierarchy involving VEX2, ESAP1, and ESB3.”

“This discovery is a real full-circle moment for me,” added Faria. “The mystery of how this parasite manages the asymmetric expression of its genetic manual has been a cold case in the back of my mind since my days as a postdoc. To finally solve it now, as the first major output of my own lab here at York, is incredibly rewarding. It’s a testament to what a fresh lab and a diverse group of scientists can achieve when they look at an old problem from a completely new angle.”

The post African Trypanosomes Use a Molecular Shredder to Avoid Detection in the Bloodstream appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis

Published

on

The acquisition of Tubulis GmbH—Gilead Sciences’ latest of the year after buying Arcells and Ouro Medicines—brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-stage data.

Continue Reading

Uncategorized

STAT+: Pharmalittle: We’re reading about FDA backing domestic production, another Gilead deal, and more

Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where clear blue skies and comfortable breezes are greeting us. Who could ask for anything more? Actually, we could — it is time to reheat the kettle for another cuppa stimulation. Our choice today is ginger peach. And here is a helpful tip — a teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are now hawking replicas — take a look. Meanwhile, here are a few tidbits to help you along. As always, do keep in touch. We appreciate feedback, criticism, and tips. …

The U.S. Food and Drug Administration used the president’s budget to propose policies aimed at encouraging domestic development and manufacturing of drugs, STAT notes. FDA Commissioner Marty Makary has said the agency needs “giant, big ideas” to counter China’s dominance in early-stage clinical development of drugs. Among the FDA’s ideas are proposals to make it easier to run early-stage trials in the U.S. and to hand an advantage to U.S.-based generics manufacturers. The Trump administration has been using a variety of policy levers to try and bring drug manufacturing to the U.S. One of the legislative proposals in the FDA’s budget justification would let domestic manufacturers of generic drugs challenge brand drug patents a month before foreign companies, a major advantage in an intensely competitive process. 

Two more drugmakers, AbbVie and Genentech, will officially start selling their medicines on the TrumpRx website, CBS News tells us. Abbvie, which struck a deal with the Trump administration in January to cut the cost of certain medicines, will sell Humira, a popular medication used to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, on the site at an 86% discount. The prescription prices on the site, however, are only available to patients who are uninsured, or whose insurance does not cover it, and who must pay the full list price out of pocket. Those with insurance coverage generally pay lower prices already. TrumpRx now sells over 61 drugs at a lower price, up from about 40 when the website went live in February. 

Continue to STAT+ to read the full story…

Read More

Published

on

Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where clear blue skies and comfortable breezes are greeting us. Who could ask for anything more? Actually, we could — it is time to reheat the kettle for another cuppa stimulation. Our choice today is ginger peach. And here is a helpful tip — a teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are now hawking replicas — take a look. Meanwhile, here are a few tidbits to help you along. As always, do keep in touch. We appreciate feedback, criticism, and tips. …

The U.S. Food and Drug Administration used the president’s budget to propose policies aimed at encouraging domestic development and manufacturing of drugs, STAT notes. FDA Commissioner Marty Makary has said the agency needs “giant, big ideas” to counter China’s dominance in early-stage clinical development of drugs. Among the FDA’s ideas are proposals to make it easier to run early-stage trials in the U.S. and to hand an advantage to U.S.-based generics manufacturers. The Trump administration has been using a variety of policy levers to try and bring drug manufacturing to the U.S. One of the legislative proposals in the FDA’s budget justification would let domestic manufacturers of generic drugs challenge brand drug patents a month before foreign companies, a major advantage in an intensely competitive process. 

Two more drugmakers, AbbVie and Genentech, will officially start selling their medicines on the TrumpRx website, CBS News tells us. Abbvie, which struck a deal with the Trump administration in January to cut the cost of certain medicines, will sell Humira, a popular medication used to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, on the site at an 86% discount. The prescription prices on the site, however, are only available to patients who are uninsured, or whose insurance does not cover it, and who must pay the full list price out of pocket. Those with insurance coverage generally pay lower prices already. TrumpRx now sells over 61 drugs at a lower price, up from about 40 when the website went live in February. 

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes

FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes

Published

on

Aiming to protect patients, the FDA sent lawmakers a wish list of legislative proposals intended to clarify and expand its oversight of updates to approved drug production processes.​ ​Read More

Continue Reading
Advertisement

Trending